This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:


trusted source


New discovery could help treat a rare and severe form of amyloidosis

Alzheimer's disease
PET scan of a human brain with Alzheimer's disease. Credit: public domain

In people with a rare condition called light chain amyloidosis, light chain proteins—which are a component of antibodies—mutate and build up in different organs. In new research published in The FEBS Journal, investigators have identified and characterized an antibody fragment that can bind to abnormal light chains to stabilize them and prevent their aggregation.

The findings could have an important clinical impact because the current prognosis for individuals with light chain amyloidosis is extremely poor, and , which rely on attacking the defective light chain-producing cells, are difficult to tolerate.

The results may also be applicable to other forms of amyloidosis, including Alzheimer's disease.

"We are excited by this finding, which has potential to provide a much-needed treatment for people diagnosed with light chain amyloidosis," said corresponding author Jillian Madine, Ph.D., of the University of Liverpool, in the UK.

More information: Enhanced stabilisation and reduced fibril forming potential of an amyloidogenic light chain using a variable heavy domain to mimic the homodimer complex, FEBS Journal (2024). DOI: 10.1111/febs.17223

Provided by Wiley
Citation: New discovery could help treat a rare and severe form of amyloidosis (2024, July 10) retrieved 23 July 2024 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

Review highlights advances and future needs in AL amyloidosis treatment


Feedback to editors